{'52WeekChange': -0.5435523,
 'SandP52WeekChange': 0.0644362,
 'address1': '9000 Virginia Manor Road',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.38,
 'askSize': 900,
 'averageDailyVolume10Day': 1589600,
 'averageVolume': 686346,
 'averageVolume10days': 1589600,
 'beta': None,
 'beta3Year': None,
 'bid': 9.45,
 'bidSize': 3000,
 'bookValue': 12.057,
 'category': None,
 'circulatingSupply': None,
 'city': 'Beltsville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.8227,
 'dayLow': 9.24,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 3.027,
 'enterpriseToRevenue': -2.165,
 'enterpriseValue': -59262060,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 19.093287,
 'fiftyTwoWeekHigh': 109,
 'fiftyTwoWeekLow': 8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 15369552,
 'forwardEps': -2.5,
 'forwardPE': -3.752,
 'fromCurrency': None,
 'fullTimeEmployees': 69,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.13533,
 'heldPercentInstitutions': 0.82338995,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/nextcure.com',
 'longBusinessSummary': 'NextCure, Inc., a clinical-stage biopharmaceutical '
                        'company, engages in discovering and developing novel '
                        'immunomedicines to treat cancer and other '
                        'immune-related diseases by restoring normal immune '
                        'function. Its lead product candidate is NC318, which '
                        'is in Phase 2 clinical trials for the treatment of '
                        'advanced or metastatic solid tumors. The company is '
                        'also developing NC410, is a novel immunomedicine '
                        'designed to block immune suppression mediated by an '
                        'immune modulator called Leukocyte-Associated '
                        'Immunoglobulin-like Receptor 1. Its discovery and '
                        'research programs include an antibody in preclinical '
                        'evaluation of other potential novel immunomodulatory '
                        'molecules that targets a novel member of the '
                        'B7-family of immunomodulatory proteins; and an '
                        'antibody in preclinical development targeting an '
                        'immune modulator that is expressed in inflamed tissue '
                        'and the tumor microenvironment in various tumor '
                        'types. NextCure, Inc. has a license agreement with '
                        'Yale University; and a research and development '
                        'collaboration with Eli Lilly and Company. The company '
                        'was founded in 2015 and is headquartered in '
                        'Beltsville, Maryland.',
 'longName': 'NextCure, Inc.',
 'market': 'us_market',
 'marketCap': 258113216,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_321460821',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -17849000,
 'nextFiscalYearEnd': 1640908800,
 'open': 9.74,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.23,
 'phone': '240 399 4900',
 'previousClose': 9.9,
 'priceHint': 2,
 'priceToBook': 0.7779713,
 'priceToSalesTrailing12Months': 9.431205,
 'profitMargins': -0.65219,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.8227,
 'regularMarketDayLow': 9.24,
 'regularMarketOpen': 9.74,
 'regularMarketPreviousClose': 9.9,
 'regularMarketPrice': 9.74,
 'regularMarketVolume': 1140035,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27517400,
 'sharesPercentSharesOut': 0.0771,
 'sharesShort': 2120531,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1233661,
 'shortName': 'NextCure, Inc.',
 'shortPercentOfFloat': 0.08229999,
 'shortRatio': 4.47,
 'startDate': None,
 'state': 'MD',
 'strikePrice': None,
 'symbol': 'NXTC',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.805,
 'twoHundredDayAverage': 34.671833,
 'volume': 1140035,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.nextcure.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20705'}